Cholesterol metabolism: a potential therapeutic target in Mycobacteria
- PMID: 28002883
- PMCID: PMC5481656
- DOI: 10.1111/bph.13694
Cholesterol metabolism: a potential therapeutic target in Mycobacteria
Abstract
Tuberculosis (TB), although a curable disease, is still one of the most difficult infections to treat. Mycobacterium tuberculosis infects 10 million people worldwide and kills 1.5 million people each year. Reactivation of a latent infection is the major cause of TB. Cholesterol is a critical carbon source during latent infection. Catabolism of cholesterol contributes to the pool of propionyl-CoA, a precursor that is incorporated into lipid virulence factors. The M. tuberculosis genome contains a large regulon of cholesterol catabolic genes suggesting that the microorganism can utilize host sterol for infection and persistence. The protein products of these genes present ideal targets for rational drug discovery programmes. This review summarizes the development of enzyme inhibitors targeting the cholesterol pathway in M. tuberculosis. This knowledge is essential for the discovery of novel agents to treat M. tuberculosis infection.
Linked articles: This article is part of a themed section on Drug Metabolism and Antibiotic Resistance in Micro-organisms. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.14/issuetoc.
© 2016 The British Pharmacological Society.
Figures






Similar articles
-
Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis.Trends Microbiol. 2011 Nov;19(11):530-9. doi: 10.1016/j.tim.2011.07.009. Epub 2011 Sep 15. Trends Microbiol. 2011. PMID: 21924910 Free PMC article. Review.
-
Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach.Br J Pharmacol. 2017 Jul;174(14):2209-2224. doi: 10.1111/bph.13810. Epub 2017 May 9. Br J Pharmacol. 2017. PMID: 28380256 Free PMC article.
-
More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis.Curr Opin Chem Biol. 2018 Jun;44:39-46. doi: 10.1016/j.cbpa.2018.05.012. Epub 2018 Jun 12. Curr Opin Chem Biol. 2018. PMID: 29906645 Free PMC article. Review.
-
Drug metabolism and antibiotic resistance in micro-organisms.Br J Pharmacol. 2017 Jul;174(14):2159-2160. doi: 10.1111/bph.13839. Epub 2017 Jun 13. Br J Pharmacol. 2017. PMID: 28463394 Free PMC article.
-
Identification of the anti-mycobacterial functional properties of piperidinol derivatives.Br J Pharmacol. 2017 Jul;174(14):2183-2193. doi: 10.1111/bph.13744. Epub 2017 Mar 23. Br J Pharmacol. 2017. PMID: 28195652 Free PMC article.
Cited by
-
Targeting Mycobacterium tuberculosis iron-scavenging tools: a recent update on siderophores inhibitors.RSC Med Chem. 2023 Sep 6;14(10):1885-1913. doi: 10.1039/d3md00201b. eCollection 2023 Oct 18. RSC Med Chem. 2023. PMID: 37859726 Free PMC article. Review.
-
New Insights into the Modification of the Non-Core Metabolic Pathway of Steroids in Mycolicibacterium and the Application of Fermentation Biotechnology in C-19 Steroid Production.Int J Mol Sci. 2023 Mar 9;24(6):5236. doi: 10.3390/ijms24065236. Int J Mol Sci. 2023. PMID: 36982310 Free PMC article. Review.
-
Dynamic Characterization of Protein and Posttranslational Modification Levels in Mycobacterial Cholesterol Catabolism.mSystems. 2020 Jan 7;5(1):e00424-19. doi: 10.1128/mSystems.00424-19. mSystems. 2020. PMID: 31911463 Free PMC article.
-
Fragment-based development of small molecule inhibitors targeting Mycobacterium tuberculosis cholesterol metabolism.bioRxiv [Preprint]. 2024 Dec 3:2024.10.28.620643. doi: 10.1101/2024.10.28.620643. bioRxiv. 2024. Update in: J Med Chem. 2025 Jul 24;68(14):14416-14441. doi: 10.1021/acs.jmedchem.5c00478. PMID: 39803573 Free PMC article. Updated. Preprint.
-
Design, Synthesis, and Antimicrobial Evaluation of New Annelated Pyrimido[2,1-c][1,2,4]triazolo[3,4-f][1,2,4]triazines.Molecules. 2020 Mar 15;25(6):1339. doi: 10.3390/molecules25061339. Molecules. 2020. PMID: 32183502 Free PMC article.
References
-
- Abuhammad A, Lack N, Schweichler J, Staunton D, Sim RB, Sim E (2011). Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N‐acetyltransferase (TBNAT) a potential target for novel anti‐tubercular agents. Protein Expr Purif 80: 246–252. - PubMed
-
- Abuhammad A, Lowe ED, McDonough MA, Shaw Stewart PD, Kolek SA, Sim E et al. (2013). Structure of arylamine N‐acetyltransferase from Mycobacterium tuberculosis determined by cross‐seeding with the homologous protein from M. marinum: triumph over adversity. Acta Crystallogr D Biol Crystallogr 69: 1433–1446. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical